David Lebowitz
Stock Analyst at BMO Capital
(4.75)
# 668
Out of 5,118 analysts
488
Total ratings
57.3%
Success rate
12.2%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Rated: Buy | $290 → $292 | $155.94 | +87.25% | 60 | Nov 5, 2026 | |
| BCAX Bicara Therapeutics | Reiterated: Buy | $35 | $8.65 | +304.62% | 3 | Nov 4, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $97 | $56.03 | +73.12% | 26 | Nov 2, 2026 | |
| IONS Ionis Pharmaceuticals | Upgraded: Buy | $66 | $39.42 | +67.43% | 56 | Nov 2, 2026 | |
| EXEL Exelixis | Rated: Hold | $54 → $60 | $69.57 | -13.76% | 20 | Oct 30, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $11 | $0.84 | +1,209.52% | 3 | Oct 20, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $9 | $4.65 | +93.55% | 2 | Sep 24, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $319 | $256.82 | +24.21% | 41 | Sep 14, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $37 | $15.82 | +133.88% | 1 | Aug 18, 2026 | |
| COGT Cogent Biosciences | Reiterated: Buy | $22 | $31.65 | n/a | 13 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 | $58.16 | n/a | 17 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $77 → $84 | $53.69 | n/a | 6 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $74.29 | n/a | 21 | Sep 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $48 | $29.87 | n/a | 5 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 → $29 | $26.84 | n/a | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $505 | $399.63 | n/a | 14 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $72 → $89 | $93.72 | n/a | 22 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $35 → $20 | $29.82 | n/a | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1.7 | $0.8097 | n/a | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $12 | $11.35 | n/a | 19 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 → $103 | $119.65 | n/a | 21 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $32 → $45 | $65.44 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2.75 | $0.4013 | n/a | 5 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12 → $14 | $4.39 | n/a | 15 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $27 | $0.0549 | n/a | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $21 | $9.54 | n/a | 13 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $25 | $20.64 | n/a | 8 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $39 | $3.68 | n/a | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $54 | $112.28 | n/a | 11 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $50 | $25.55 | n/a | 2 | Jul 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $17 | $2.33 | n/a | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $0.0001 | n/a | 3 | Dec 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $60 | $17.82 | n/a | 1 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $126 | $547.09 | n/a | 1 | Jan 9, 2015 |
Alnylam Pharmaceuticals
Nov 5, 2026
Rated: Buy
Price Target: $290 → $292
Current: $155.94
Upside: +87.25%
Bicara Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $35
Current: $8.65
Upside: +304.62%
BioMarin Pharmaceutical
Nov 2, 2026
Reiterated: Buy
Price Target: $97
Current: $56.03
Upside: +73.12%
Ionis Pharmaceuticals
Nov 2, 2026
Upgraded: Buy
Price Target: $66
Current: $39.42
Upside: +67.43%
Exelixis
Oct 30, 2026
Rated: Hold
Price Target: $54 → $60
Current: $69.57
Upside: -13.76%
Perspective Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $11
Current: $0.84
Upside: +1,209.52%
Prime Medicine
Sep 24, 2026
Reiterated: Buy
Price Target: $9
Current: $4.65
Upside: +93.55%
Ascendis Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $319
Current: $256.82
Upside: +24.21%
Aktis Oncology
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $37
Current: $15.82
Upside: +133.88%
Cogent Biosciences
Sep 4, 2025
Reiterated: Buy
Price Target: $22
Current: $31.65
Upside: n/a
Sep 3, 2025
Reiterated: Hold
Price Target: $17
Current: $58.16
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: $77 → $84
Current: $53.69
Upside: n/a
Sep 1, 2025
Reiterated: Buy
Price Target: $67
Current: $74.29
Upside: n/a
Aug 20, 2025
Reiterated: Buy
Price Target: $70 → $48
Current: $29.87
Upside: n/a
Aug 20, 2025
Reiterated: Hold
Price Target: $38 → $29
Current: $26.84
Upside: n/a
Aug 19, 2025
Rated: Buy
Price Target: $505
Current: $399.63
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $72 → $89
Current: $93.72
Upside: n/a
Aug 15, 2025
Downgraded: Hold
Price Target: $35 → $20
Current: $29.82
Upside: n/a
Aug 11, 2025
Reiterated: Hold
Price Target: $1.5 → $1.7
Current: $0.8097
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: $10 → $12
Current: $11.35
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: $88 → $103
Current: $119.65
Upside: n/a
Feb 11, 2025
Reiterated: Sell
Price Target: $32 → $45
Current: $65.44
Upside: n/a
Nov 5, 2021
Reiterated: Hold
Price Target: $3 → $2.75
Current: $0.4013
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $12 → $14
Current: $4.39
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $27
Current: $0.0549
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $20 → $21
Current: $9.54
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $25
Current: $20.64
Upside: n/a
Aug 24, 2021
Initiated Coverage: Hold
Price Target: $39
Current: $3.68
Upside: n/a
Aug 3, 2021
Reiterated: Buy
Price Target: $57 → $54
Current: $112.28
Upside: n/a
Jul 16, 2021
Reiterated: Buy
Price Target: $52 → $50
Current: $25.55
Upside: n/a
Apr 30, 2021
Reiterated: Sell
Price Target: $15 → $17
Current: $2.33
Upside: n/a
Dec 7, 2020
Reiterated: Hold
Price Target: $20
Current: $0.0001
Upside: n/a
Oct 2, 2017
Upgraded: Buy
Price Target: $60
Current: $17.82
Upside: n/a
Jan 9, 2015
Initiated Coverage: Hold
Price Target: $126
Current: $547.09
Upside: n/a